75 reports of this reaction
1.2% of all LEVOCARNITINE reports
#19 most reported adverse reaction
HOSPITALISATION is the #19 most commonly reported adverse reaction for LEVOCARNITINE, manufactured by Leadiant Biosciences, Inc.. There are 75 FDA adverse event reports linking LEVOCARNITINE to HOSPITALISATION. This represents approximately 1.2% of all 6,090 adverse event reports for this drug.
Patients taking LEVOCARNITINE who experience hospitalisation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOSPITALISATION is a less commonly reported adverse event for LEVOCARNITINE, but still significant enough to appear in the safety profile.
In addition to hospitalisation, the following adverse reactions have been reported for LEVOCARNITINE:
The following drugs have also been linked to hospitalisation in FDA adverse event reports:
HOSPITALISATION has been reported as an adverse event in 75 FDA reports for LEVOCARNITINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOSPITALISATION accounts for approximately 1.2% of all adverse event reports for LEVOCARNITINE, making it a notable side effect.
If you experience hospitalisation while taking LEVOCARNITINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.